In a recent span of two weeks, Aperiomics has been named a finalist in two Greater Washington, DC, award competitions.
The Northern Virginia Chamber of Commerce selected Aperiomics as a finalist in the Health & Life Sciences Innovator of the Year category for the 2nd Annual Greater Washington Innovation Awards. Winners will be announced live at an awards ceremony on Thursday, April 21, 2016, at the Hyatt Regency Reston. These awards honor the people and organizations “who introduce new methods, ideas and products to improve our lives and challenge the status quo. Their innovations create new consumers and markets, and ultimately transform the way we do business.”
Women in Technology (WIT) announced Aperiomics and CEO Crystal Icenhour as one of five finalists in the Small Business Entrepreneur category for its 17th Annual Leadership Awards. Based in Falls Church, VA, WIT conducts this awards program to highlight women working in the Greater Washington, DC region who “have exemplified unique vision, leadership and profound success in the technology industry.” The awards program recognizes women leaders in nine categories; the winners will be announced live at the Leadership Awards Banquet on May 19, 2016, also at the Hyatt Regency Reston.
As Aperiomics CEO Crystal Icenhour, PhD, notes, “It’s highly gratifying for our young company to be recognized by these two organizations. We’re proud to be in the company of our fellow honorees and pleased that this award process can help to raise awareness of our innovative technology that holds so much potential for improving health.”
Based in Sterling, VA, Aperiomics was founded in October 2013 as a spinoff from the Computational Biology Institute at George Washington University’s Virginia Science and Technology Campus in Sterling. The company combines genomics and informatics in an innovative way to produce faster and more accurate results than culture-based or even other molecular-based diagnostic approaches.
From a single test, Aperiomics can simultaneously test for all pathogens whether bacteria, virus, fungus or parasite. The sample can be tissue, plant, animal, or environmental. Based on its unique process that capitalizes on high-throughput Next-generation sequencing and advanced Bayesian statistics, Aperiomics can not only find a “needle in a haystack” but can also reveal that a “needle” is lurking there – even if it is a formerly unknown pathogen. This effective system translates into improved human and animal health, reduced risk to public health, and significant health care cost savings.
Recently, Aperiomics announced its second National Science Foundation Award in a year. With this Small Business Innovation Research (SBIR) Phase II grant, the company’s NSF funding through a total of three grants has now reached nearly a million dollars. In addition to support from the National Science Foundation’s SBIR and iCORP programs, Aperiomics has also received funding from the Center for Innovative Technologies of Herndon, VA, and from private investments.
For more information, please visit www.aperiomics.com or look for the company on LinkedIn, Twitter and AngelList.